Sleep apnea syndrome and atherosclerosis: VE-Cadherin as a new antiatherogenic target?

O. Harki (Grenoble, France), S. Bouyon (Grenoble, France), E. Lemarié (Grenoble, France), A. Demory (Grenoble, France), C. Chirica (Grenoble, France), I. Vilgrain (Grenoble, France), J. Pépin (Grenoble, France), G. Faury (Grenoble, France), A. Briançon-Marjollet (Grenoble, France)

Source: International Congress 2022 – Translational research in sleep apnoea: from the molecule and the signal to the clinic

Session: Translational research in sleep apnoea: from the molecule and the signal to the clinic
Session type: Oral Presentation
Number: 4383

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Harki (Grenoble, France), S. Bouyon (Grenoble, France), E. Lemarié (Grenoble, France), A. Demory (Grenoble, France), C. Chirica (Grenoble, France), I. Vilgrain (Grenoble, France), J. Pépin (Grenoble, France), G. Faury (Grenoble, France), A. Briançon-Marjollet (Grenoble, France). Sleep apnea syndrome and atherosclerosis: VE-Cadherin as a new antiatherogenic target?. 4383

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.